Abstract 2531 (Board 178): Novel immune checkpoint blockade GV20-0251 (anti-IGSF8) demonstrates preliminary monotherapy efficacy in advanced melanoma patients with primary resistance to anti-PD1

Kristopher Wentzel, Julio A. Peguero, Shivaani Kummar, Janice M. Mehnert, Aung Naing, Alexander I. Spira, Justin F. Gainor, Omid Hamid, Inderjit Mehmi, Justin T Moyers, Karim Benhadji, Leila Alland, Hong Xiao, Xihao Hu, Xingfeng Bao, Tengfei Xiao, Caibin Sheng, Jie Chen, Ying Gong, X. Shirley Liu, Patricia LoRusso

IGSF8 is a novel immune checkpoint

- IGSF8 is expressed in antigen presentation-defective “cold” tumors to suppress NK cell cytotoxicity, DC antigen presentation and T cell priming
- Blocking IGSF8 by GV20-0251 activates both innate and adaptive immunity to kill tumors



Li et al, Cell 2024

GV20-0251-100 study enrollment



Schedule S1: D1 D8 Q3W
Schedule S2: D1 Q3W
pts: patients
bf: backfill



Characteristics	n=42
Age, years	
Median	61
Range	21-84
Sex, n (%)	
Male	17 (40)
Female	25 (60)
Race, n (%)	
Asian	3 (7)
Black or African American	3 (7)
White	34 (81)
Other	2 (5)
ECOG performance status, n (%)	
0	21 (50)
1	21 (50)
Prior Systemic Therapies, n (%)	
Median=4, range (1-11)	
1	5 (12)
2	12 (29)
≥3	25 (60)

Monotherapy safety

- 55% of pts had TRAEs, all Gr1/2 except 1 Gr3 pneumonitis
- The most common TRAEs were fatigue and rash (12% each)
- No DLTs and no dose-dependent trends in AEs

Preliminary monotherapy efficacy

- In 38 evaluable pts (17 with CM), 3 PRs and 15 SDs were observed



- In 9 cutaneous melanoma (CM) pts with primary resistance to anti-PD1, 3 confirmed PRs and 3 w/ tumor shrinkage were observed (DCR 66.6%)
- 2 of the PR pts had liver metastases and 1 is on treatment >14 mos



PK/Target Occupancy/ PD/ Biomarker

- Linear PK with T1/2 of 26 days and full target occupancy observed at ≥10 mg/kg
- No significant serum cytokine elevation or anti-drug antibody signals
- Tumors showed increased NK and T cell infiltration upon GV20-0251 treatment
- 7/7 of CM have baseline IGSF8 expression by IHC (TPS range 15-100%), and 2/2 responders each has 95% TPS





Conclusion

- **GV20-0251 (anti-IGSF8) demonstrated a favorable safety profile in advanced solid tumor patients**
- **GV20-0251 (anti-IGSF8) showed promising preliminary efficacy in cutaneous melanoma (CM) patients with primary resistance to anti-PD1**

Acknowledgements

We thank the patients and their families, investigators, research nurses, coordinators and staff for supporting the GV20-0251-100 study.

GV20 THERAPEUTICS